Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ROIC - WACC | 73.3% | (58.2%) | (121.9%) | (146.2%) | (105.6%) | (37.9%) | (32.5%) | (53.8%) | 98.3% | 30.8% | 18.3% | 20.3% | 19.6% | 21.5% | 39.8% | 27.2% | 40.4% | 115.2% | 46.3% | 23.9% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month ROIC - WACC is 19.8%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual ROIC - WACC for Regeneron Pharmaceuticals, Inc. have been 42.5% over the past three years, and 40.8% over the past five years.
As of today, Regeneron Pharmaceuticals, Inc.'s ROIC - WACC is 19.8%, which is higher than industry median of (127.8%). It indicates that Regeneron Pharmaceuticals, Inc.'s ROIC - WACC is Good.